Merck and the National Sleep Foundation Urge Insomnia Sufferers to Prioritize Sleep and Move Beyond Tired
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Leerink Partners Reiterates Market Perform on Merck (MRK) Following 3Q EPS Beat
October 28, 2015 9:31 AM EDTLeerink Partners reiterated a Market Perform rating and $67.00 price target on Merck (NYSE: MRK) following the company's 3Q earnings results. MRK reported a $0.04 EPS beat. US sales of Januvia/Janumet increased by 22%, but was benefited by ~$100M due to the timing of consumer buying that is expected to negatively impact future quarters.
Analyst Seamus Fernandez... More
Leerink Affirms Merck (MRK) at 'Market Perform'; Additional KEYTRUDA Data Still Needed
October 26, 2015 2:29 PM EDTLeerink affirms Merck (NYSE: MRK) at Market Perform with a price target of $67 after the company announced topline results from the KEYNOTE-010 study of KEYTRUDA (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective.
Analyst Seamus Fernandez commented: This morning, MRK announced the successful... More
Merck (MRK) Announces KEYTRUDA Met Primary Endpoint in KEYNOTE-010 Study
October 26, 2015 9:02 AM EDTMerck (NYSE: MRK) announced topline results from the KEYNOTE-010 study of KEYTRUDA® (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective.
KEYNOTE-010 is a randomized, pivotal Phase 2/3 trial comparing two doses of KEYTRUDA (the FDA-approved 2mg/kg dose and a higher, investigational 10mg/kg dose, each given every 3 weeks), to docetaxel, a commonly used chemotherapy. Patients were enrolled who had failed prior systemic therapy for advanced NSCLC and whose tumors had PD-L1 (programmed death... More
